BRAF and Langerhans cell histiocytosis: Therefore, findings regarding CHC in our sample are representative for LCH patients treated in the past, but may not be generalizable (or necessarily relevant) to those treated nowadays with novel treatment modalities such as BRAF or MEK inhibitors.